Overall, our studies indicate that the oncogenic function of METTL16 relies on its role in reprogramming mRNA translation in cancer (e.g., HCC) cells, and highlight the therapeutic potential of targeting the METTL16/eIF3a axis and mRNA translation program for cancer treatment. The gene discussed is EIF3A; the disease is hepatocellular carcinoma.